US COVID-19 Relief Law Boosts Pharmaceutical Manufacturing Programs; Is More To Come?
Executive Summary
$10bn here and $6bn there on top of what’s left from earlier CARES Act gives government more options on COVID-19 medical countermeasures.
You may also be interested in...
Biden Infrastructure Plan Would Boost Pandemic Preparedness, Biotech R&D, US Manufacturing
Tax hike would fund $30bn for pandemic preparations and billions more for biotech R&D and rural manufacturing jobs that are part of comprehensive infrastructure renewal proposal.
Abernethy’s Departure From US FDA Gives Next Commissioner Options For A New Number Two
Janet Woodcock has been in the lead in the commissioner race for months without an announcement, but now serious doubts are being cast on her candidacy, including the tone of remarks at a White House press briefing.
Don’t Let The Quiet Fool You: The US Drug Pricing Debate Is At A Critical Point
There won’t be a lot of legislative action in Congress in the weeks following passage of the $1.9tn American Rescue Plan. But the coming months are a critical time for the drug industry to try to set the terms for how it is treated in the next major bill later this year, and the stakes could not be higher.